Immunomedics (IMMU) Misses Q1 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- AMD gets bullish pre-earnings call from Lynx as server CPU demand accelerates
- Marathon Petroleum to sell two refineries to CVR Energy for $4.2B
- Moderna shares rise ahead of Thursday earnings report
- AMD forecast eases AI spending fears as data-center sales surge
- Broadcom shares climb as AI chip financing deal supports rally
- After-Hours Movers: AMD, SMCI, SWKS, NRIX, TOST, BKNG
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
Immunomedics Announces First Quarter Fiscal 2017 Results and Clinical Program Developments
November 2, 2016 4:01 PM EDTMORRIS PLAINS, N.J., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq: IMMU) today reported financial results for the first quarter ended September 30, 2016. The Company also highlighted recent key developments and planned activities for its clinical pipeline.
First Quarter Fiscal 2017 Results
Total revenues for the first quarter ended September 30, 2016, were $0.7 million, the same amount... More



